

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL OMB Number: 3235-0076 Expires: August 31, 2015 Estimated Average burden hours per response: 4.0

IK (Filer ID Number)	Previous Name(s)	▼ None	Entity Type
001645469			© Corporation
ame of Issuer	<u> </u>		C Limited Partnership
Monopar Therapeutics			
risdiction of			Limited Liability Company
corporation/Organization			General Partnership
DELAWARE			C Business Trust
ear of Incorporation/Organiz	ation		C Other
Over Five Years Ago			- Other
Within Last Five Years (Specify Year)	2015		
Vet to Be Formed			

2. Principal Place of	Business and C	ontact Informati	on
Name of Issuer			
Monopar Therapeutics			
Street Address 1	S	Street Address 2	
5 REVERE DRIVE, SUITE 200			
City	State/Province/Country	ZIP/Postal Code	Phone No. of Issuer
NORTHBROOK	ILLINOIS	60062	6143958936

3. Related Per	sons					
Last Name		First Name		Middle	Name	
Robinson		Chandler		D.		
Street Address 1			Street Address 2			
5 Revere Dr, Suite 20	00					
City		State/Province/C	Country	ZIP/Pos	stal Code	
Northbrook		ILLINOIS		60062		
Relationship:	Execut	tive Officer	□ Director		Promoter	
Clarification of Respons	e (if Necessar	y)				
		<u> </u>				
Last Name		First Name		Middle	Name	
Starr		Christopher		M.		
Street Address 1			Street Address 2	<u> </u>		
5 Revere Dr, Suite 20	00					
City		State/Province/C	Country	ZIP/Pos	stal Code	

Northbrook	ILLINOIS		60062
Relationship:	Executive Officer	☑ Director	Promoter
Clarification of Response (if	Necessary)		
Last Name	First Name		Middle Name
Mazar	Andrew		P.
Street Address 1		Street Address	2
5 Revere Dr, Suite 200			
City	State/Province/	Country	ZIP/Postal Code
Northbrook	ILLINOIS		60062
Relationship:	Executive Officer	✓ Director	Promoter
Clarification of Response (if	Necessary)		
Last Name	First Name		Middle Name
Brown	Michael		J.
Street Address 1		Street Address	2
5 Revere Dr, Suite 200			
City	State/Province/	Country	ZIP/Postal Code
Northbrook	ILLINOIS		60062
Relationship:	Executive Officer	Director	Promoter
Clarification of Response (if	Necessary)		
4. Industry Group		_	
	Health C	are	C Retailing
Agriculture		echnology	Retaining
Banking & Financial Ser	Heal	th Insurance	C Restaurants
0			
C Commercial Banking	- 1103	pitals & Physicians	Technology
C Insurance	C Phai	rmaceuticals	Technology C Computers
	C Pha		A 50
C Insurance C Investing	C Phai	rmaceuticals	C Computers
C Insurance C Investing C Investment Banking	C Phan C Other	rmaceuticals	C Computers C Telecommunications
C Insurance C Investing C Investment Banking C Pooled Investment F	C Phan C Other	rmaceuticals er Health Care	C Computers C Telecommunications C Other Technology
C Insurance C Investing C Investment Banking C Pooled Investment F Other Banking & Fin	C Phai C Other und nancial C Manufact Real Esta	rmaceuticals er Health Care turing	C Computers C Telecommunications C Other Technology Travel
C Insurance C Investing C Investment Banking C Pooled Investment F Other Banking & Fin C Services C Business Services Energy	O Phan O Other und nancial O Manufact Real Esta	rmaceuticals er Health Care turing ete emercial	C Computers C Telecommunications C Other Technology Travel C Airlines & Airports
C Insurance C Investing C Investment Banking C Pooled Investment F Other Banking & Fin C Services C Business Services	C Phan C Other und nancial C Manufact Real Esta C Com	rmaceuticals er Health Care turing	C Computers C Telecommunications C Other Technology Travel C Airlines & Airports C Lodging & Conventions

Other Real Estate

C Environmental Services

C Oil & Gas	
C Other Energy	
- 1 0:	
5. Issuer Size	
Revenue Range No Revenues	Aggregate Net Asset Value Range No Aggregate Net Asset Value
\$1 - \$1,000,000	S1 - \$5,000,000
\$1,000,001 - \$5,000,000	S5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000	© \$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,000,000
Over \$100,000,000	Over \$100,000,000
Decline to Disclose	C Decline to Disclose
Not Applicable	C Not Applicable
S Federal Evenntion	n(s) and Exclusion(s) Claimed (select all that
apply)	(a) and Exolabion(b) Claimed (select all that
Pulo 504(b)(1) (not (i) (ii)	
or (iii))	L Rule 505
Rule 504 (b)(1)(i)	▼ Rule 506(b)
Rule 504 (b)(1)(ii)	Rule 506(c)
Rule 504 (b)(1)(iii)	Securities Act Section 4(a)(5)
	Investment Company Act Section 3(c)
1	
7. Type of Filing	
New Notice Date of First	Sale First Sale Yet to Occur
_	That Sale Tet to Octur
Amendment	
B. Duration of Offering	g
oes the Issuer intend this offering	to last more than one year?
oes the issuer intend this oriering	to last more than one year.
9. Type(s) of Securities	es Offered (select all that apply)
Pooled Investment Fund Interests	▼ Equity
Tenant-in-Common Securities	☐ Debt
Mineral Property Securities	Option, Warrant or Other Right to
Security to be Acquired Upon	Acquire Another Security
Exercise of Option, Warrant of Other Right to Acquire Securit	·
Sense ragne to require Securit	₩
10. Business Combin	ation Transaction
s this offering being made in conne	(42)
ransaction, such as a merger, acqui	isition or exchange offer? Yes No
larification of Response (if Necessa	ary)

11. Minimum Investment	
Minimum investment accepted from any outside investor	\$ 120000 USD
12. Sales Compensation	
Recipient	Recipient CRD Number None
(Associated) Broker or Dealer None	(Associated) Broker or Dealer CRD Number None
Street Address 1	Street Address 2
City	State/Province/Country ZIP/Postal Code
State(s) of Solicitation	☐ All States
13. Offering and Sales Amour	nte
13. Offering and Sales Afficult	ito
Total Offering Amount \$ 10000000	USD ☐ Indefinite
Total Amount Sold \$ 0	USD
Total Remaining to be \$ 10000000	USD Indefinite
Sold	
Clarification of Response (if Necessary)	
14. Investors	
14. 111/63(013	
Select if securities in the offering have be do not qualify as accredited investors,	
Number of such non-accredited investor offering	s who already have invested in the
Regardless of whether securities in the o	· IV
persons who do not qualify as accredited of investors who already have invested in	
15. Sales Commissions & Fin	ders' Fees Expenses
	·
Provide separately the amounts of sales commission expenditure is not known, provide an estimate and	ons and finders' fees expenses, if any. If the amount of an d check the box next to the amount.
Sales Commissions \$ 0	USD Estimate
Finders' Fees \$ 0	USD Estimate
Clarification of Response (if Necessary)	

16. Use of Proceeds

any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.					
\$	0	USD	Estimate		

Clarification of Response (if Necessary)

In the ordinary course of business, the issuer likely may use some of the proceeds of the offering to pay salaries and consulting fees to certain of its executive officers and directors.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not
 disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule
 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Monopar Therapeutics	Chandler D. Robinson	Chandler D. Robinson	СЕО	2017-03-28